Joint collaboration to speed up the development of new TB drug regimes

Just a few days before the World TB Day 2010, a new initiative known as the Critical Path to TB Drug Regimens (CPTR) was launched, aiming to accelerate the development of new, safe and shorter duration TB drug regimens by testing promising new drug candidates together early in the development pipeline. CPTR is engaging pharmaceutical companies, government and regulatory agencies, potential donors, academia, and civil society to speed availability of new drug regimens that are effective against both drug-susceptible and drug-resistant TB–with the potential to save millions of lives.

The event which took place on 18 March 2010, featured keynote address by FDA Commissioner Hamburg, followed by a panel of experts which included Prof. Charles Mgone, EDCTP Executive Director.

To learn more about this initiative, please visit http://www.c-path.org/cptr.cfm.
Download here the CPTR Statement of Principles (PDF)